Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

December 12, 2023

Read More

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

May 23, 2023

Read More

Obsidian Therapeutics to Present at RBC Capital Markets Healthcare Private Company Conference

December 14, 2022

Read More

We are pioneers in cell and gene therapy

Leading the next generation of engineered therapeutics

Our Platform

Our proprietary
cytoDRiVE platform

Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule

Read More


Join Our Team

Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.


Read More